Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA's Generics Program Reaches 'Steady State' Milestone

Executive Summary

OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.

You may also be interested in...



GDUFA Research Impacting Generic Development, ANDA Approvals

Increases in approved ANDAs that were affected by GDUFA research shows the importance of the US FDA’s regulatory science program.

Generic Review At US FDA: Record Month Completes Approval Volume Recovery

With 96 full ANDA approvals and 30 tentative approvals, July was the most productive month since GDUFA launched.

Generics Office At US FDA Could Get New Director Before Uhl Departs

Kathleen Uhl gave seven months' notice of her retirement, which may allow new director to be hired and on-boarded before she departs.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB002452

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel